Bronchodilators Global Market Report 2024

The bronchodilators market size has grown strongly in recent years. It will grow from $30.43 billion in 2023 to $32.93 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be attributed to several factors, including the increasing geriatric population, a rising incidence of asthma, growing funding by government organizations for healthcare, an increase in the aging population, and the escalating levels of air pollution across the globe.

The bronchodilators market size is expected to see strong growth in the next few years. It will grow to $43.25 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The anticipated growth in the forecast period can be attributed to various factors, including the increasing prevalence of Chronic Obstructive Pulmonary Disease (COPD), rising awareness about the treatment of lung diseases coupled with escalating research and development efforts, an increase in the prevalence of pulmonary disorders, a rise in disposable income, and the increasing rates of smoking. Key trends expected in the forecast period encompass advanced clinical research and innovative treatment strategies, growing technological advancements in respiratory care, a high prevalence of lung diseases such as COPD and asthma, new product launches in the bronchodilator market, and a rising number of patients with acute respiratory infections.

The escalating prevalence of chronic obstructive pulmonary disease (COPD) is poised to drive the growth of the bronchodilator market in the foreseeable future. COPD, characterized by chronic inflammation of the airways and obstruction or limitation of airflow, represents a significant health challenge globally. Bronchodilators play a crucial role in COPD management by relaxing the muscles around the airways, thereby facilitating the opening of air passages and easing breathing difficulties. For instance, data from a report by the Scottish Public Health Observatory in March 2023, led by Public Health Scotland, revealed a notable increase in COPD rates as the impact of COVID-19 began to subside. The rate of COPD cases per 100,000 individuals surged from 83.2 to 97.6 among males and from 72.6 to 97.3 among females. Consequently, the rising prevalence of COPD serves as a primary driver propelling the growth of the bronchodilator market.

Prominent players in the bronchodilator market are strategically focused on the development of innovative products to cater to evolving patient needs and enhance treatment outcomes. One notable innovation gaining traction is fixed-dose triple-drug combinations - a medication formulation containing three active ingredients in predetermined doses within a single formulation. For example, in January 2023, Lupin, a leading pharmaceutical firm based in India, introduced DIFIZMA, a fixed-dose triple-drug bronchodilator comprising indacaterol, glycopyrronium, and mometasone for asthma management. DIFIZMA, available as a dry powder inhalation, stands out as the sole fixed-dose combination approved by the Drug Controller General of India (DCGI) for inadequately controlled asthma treatment. This innovative formulation demonstrates efficacy in improving lung function, enhancing symptom control, and reducing exacerbations in asthma patients. By offering such advanced solutions, companies such as Lupin aim to address unmet medical needs and contribute to the continued growth and advancement of the bronchodilator market.

In February 2023, AstraZeneca plc, a prominent pharmaceutical and biotechnology company headquartered in the UK, completed the acquisition of CinCor Pharma Inc. for $1.8 billion. This strategic move was driven by the shared goal of developing innovative treatments for uncontrolled hypertension and chronic kidney disease. Additionally, the acquisition is anticipated to bolster AstraZeneca's respiratory portfolio, which encompasses various bronchodilator products. CinCor Pharma, a US-based clinical-stage biopharmaceutical company specializing in the development of bronchodilator-related products, adds valuable expertise to AstraZeneca's endeavors in this therapeutic area.

Major companies operating in the bronchodilators market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Thermo Fisher Scientific, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Siemens Healthcare GmbH, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Quest Diagnostics Incorporated., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Vectura Group Limited, Foundation Medicine Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Kissei Pharmaceutical Co.Ltd., Mitsubishi Tanabe Pharma, Theron Pharmaceuticals, Viatris Inc.

North America was the largest region in the bronchodilators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bronchodilators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bronchodilators are medications designed to make breathing easier by relaxing the muscles in the lungs and widening the airways (bronchi). They are commonly employed in the treatment of long-term conditions characterized by narrow and inflamed airways, such as asthma and chronic obstructive pulmonary disease (COPD).

The main types of bronchodilators include beta-adrenergic bronchodilators, anticholinergic bronchodilators, xanthine derivatives, and others. Beta-adrenergic bronchodilators, a specific class of medications, function by binding to beta-adrenergic receptors in the smooth muscles of the airways. This binding induces relaxation and dilation of the airways, improving airflow and alleviating symptoms such as wheezing, coughing, and shortness of breath. These bronchodilators can be administered through various routes such as oral, nasal (inhalation), and injectable. They are used for treating conditions such as asthma, COPD, allergic reactions, breathing problems, and other indications. The end users of bronchodilators include hospitals, specialty clinics, and various healthcare facilities.

The bronchodilators market research report is one of a series of new reports that provides bronchodilators market statistics, including bronchodilators industry global market size, regional shares, competitors with a bronchodilators market share, detailed bronchodilators market segments, market trends and opportunities, and any further data you may need to thrive in the bronchodilators industry. This bronchodilators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bronchodilators market consists of sales of albuterol (proair, ventolin, proventil), formoterol (foradil, perforomist), salmeterol (serevent), tiotropium (spiriva) and ipratropium (atrovent). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.